Reporting Manager
POINT72 ASSET MANAGEMENT, L.P.
Symbol
BCYC
Shares outstanding
47,531,483 shares
Disclosed Ownership
4,230,302 shares
Ownership
8.9%
Form type
SCHEDULE 13G
Filing time
20 Dec 2024, 16:05:11 UTC
Date of event
13 Dec 2024
Next filing
15 May 2025

Key filing fact

Point72 Asset Management, L.P. disclosed 8.9% ownership in BICYCLE THERAPEUTICS PLC Ordinary shares, nominal value 0.01 GBP per share (BCYC) on 13 Dec 2024.

Key facts

  • Point72 Asset Management, L.P. filed SCHEDULE 13G for BICYCLE THERAPEUTICS PLC Ordinary shares, nominal value 0.01 GBP per share (BCYC).
  • Disclosed ownership: 8.9%.
  • Date of event: 13 Dec 2024.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 20 Dec 2024, 16:05.

Research use

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting persons

Reporting managers (3)

Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
POINT72 ASSET MANAGEMENT, L.P. 8.9% 4,230,302 0 4,230,302 /s/ Jason M. Colombo Jason M. Colombo, Authorized Person
POINT72 CAPITAL ADVISORS, INC. 8.9% 4,230,302 0 4,230,302 /s/ Jason M. Colombo Jason M. Colombo, Authorized Person
STEVEN A. COHEN 8.9% 4,230,302 0 4,230,302 /s/ Jason M. Colombo Jason M. Colombo, Authorized Person
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .